Article
Sex differences in GLP-1 signaling across species
2025-03-18
Abstract excerpt
Two billion humans are currently overweight or obese 1 . While glucagon-like peptide 1 receptor (GLP1R) agonists have emerged as the most promising treatment for this epidemic, side effects including nausea and vomiting constitute a significant obstacle to their use. Of the patients currently being treated, women represent nearly 70%. While early studies have noted sex differences in the response to these drugs,...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 6a2e8e3c-35a6-54a6-b7ec-f2267d87f435
- DOI
- 10.1101/2025.03.17.643822
